Monograph
C09AA10 - Trandolapril |
Propably not porphyrinogenic |
PNP |
Rationale
Presystemic metabolism. To a large part not metabolised. No data pointing to CYP-interaction. Two references stating (probable) non-porphyrinogenicity.
Chemical description
Prodrug, hydrolyzed to trandoprilate, ACE-inhibitor. Low bioavailability (4-14%) due to incomplete absorbtion and presystemic metabolism. 36-95% of the aborbed dose is excreted in unchanged form by the kidneys. South African list: use with care. French list: authorized.
Therapeutic characteristics
Less common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and obstipation.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Denmark
Poland
Luxembourg
Latvia© NAPOS 2024